Cgix 201506

Investor PresentationJune 2015

Cancer Genetics, Inc.Nasdaq

(CGIX)

Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 2

This presentation contains forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future

growth in research, technology, clinical development and potential opportunities for Cancer Genetics,

Inc. products and services, along with other statements about the future expectations, beliefs, goals,

plans, or prospects expressed by management constitute forward-looking statements. Any statements

that are not historical fact (including, but not limited to, statements that contain words such as "will,"

"believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking

statements. Forward-looking statements involve risks and uncertainties, including, without limitation,

risks inherent in the development and/or commercialization of potential products, risks of cancellation of

customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be

realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain

future capital, maintenance of intellectual property rights and other risks discussed in the Company's

Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended March 31, 2015

along with other filings with the Securities and Exchange Commission. These forward-looking statements

speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-

looking statements.

Forward-Looking Statement


Fact Sheet

Market Cap $95.07 Mn

Stock Price $9.13 [5/11/2015]

Ticker Symbol Nasdaq: CGIX

Qtrly Revenue (yoy) 117.6%

Total Cash $28.6 Mn

Facilities

• Rutherford, NJ

• Raleigh, NC

• Hyderabad, India

• Shanghai, China

18,000 sq. ft.

28,000 sq. ft.

14,000 sq. ft.

3,000 sq. ft.

Clients• Cancer Centers

• Physician Offices

• Research Orgs.

• Hospitals

• Biotech

• Biopharma

Products 8 Launched Products

Patents 8 US Issued Patents

Cancer Genetics, Inc.

*Financial data as of 5/12/2015


Recent Highlights2014-2015

Agreement with Three Rivers

Provider Network expanded

FHACT® partnership with

PathAdvantage

Partnership with AstraZeneca to

provide biomarker & MDx testing

Biopharma contracts increased to

$30 Mn+

NYS licensure for FHACT®

Agreement with America’s Choice

Provider Network®

Focus::CLL™ selected for use in

global clinical trial by leading

biotech company

Acquisition of

Gentris

Corporation

Acquisition of

BioServe India

Collaborative kidney cancer

study with Cleveland Clinic

results announced

Collaborations with Keck

Medicine of USC & Beth Israel

Deaconess Medical Center for

diffuse large B-cell lymphoma

Next Gen Sequencing

Collaboration with Columbia

University for myelodysplastic

syndromes & acute myeloid

leukemia

Multi-Year Collaboration with

Moffitt Cancer Center for

genomics-based prediction of

chemotherapy side effects

Acquisitions

Research

Collaborations

Business

Growth

Awarded

additional

kidney cancer

patent for

UroGenRA®-

Kidney

Awarded two

cervical cancer

patents for

FHACT®

Launch of MatBA®-FL &

MatBA®-MCL for follicular

lymphoma & mantle cell

lymphoma

Launch of CALR mutation

test for acute leukemias &

myeloproliferative

neoplasms

Upgraded MatBA®-CLL/SLL

algorithm for patient

stratification; add’l CLIA &

NYS Licensure

Launch of Focus::CLL™,

Focus::Myeloid™, &

Focus::Hotspot™ NGS

panels

Product

Launches Patents


Genomic Testing has Paved the Way for Significant

Advancements in Diagnosis & Targeted Treatment Options

Comprehensive

Report

Proprietary

Products

Focused

Oncology Lab

OUR INTEGRATED APPROACH TO MOLECULAR

TESTING BRINGS BENEFITS ACROSS THE ENTIRE

ONCOLOGY ECOSYSTEM

DIAGNOSISDo I have cancer and if so,

what type?

PROGNOSISWhat course will my

cancer take? What should I expect?

THERANOSISWhat are my treatment

options? Which drug is the best fit for me?


Business Overview

8 Genomic Tests Launched

Research & Development Biotech/Biopharma

3,622

5,9466,871

11,912

2011 2012 2013 2014

Clinical Test Volume (2011-2014)

17 Current Research Collaborations

Clinical Laboratory

NGS Panel Development:

Contracts with 6 of the top 10 pharma companies

Hematologic

Cancers:

Urogenital

Cancers:

Cervical

Cancer:

35% CAGR


We are Positioned to be the Oncology Diagnostics

Partner of Choice in Attractive Markets

Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics

U.S.

China

India

$6 Bn

$1 Bn

N/A

Clinical

$2.5 Bn

$0.4 Bn

$1 Bn

Biopharma


Major Drivers for our Proprietary Programs

Is there an unmet patient need?

Is it unique & can it drive an IP-ready position?

Can we leverage the existing routine sample?

Can we validate and collaborate with major

research centers?

Can it be offered as part of our Complete™

programs?

1

2

3

4

5


Eight US Patents Awarded

7 Proprietary Diagnostic Products Addressing 1.2 Mn

Cases Globally Launched & in Market

Hematologic Cancers Cases per Year (global) CGI Test

Chronic Lymphocytic Leukemia 106,770 Focus::CLL™, MatBA®-CLL/SLL

Diffuse Large B-Cell Lymphoma 142,360 MatBA®-DLBCL

Follicular Lymphoma 62,300 MatBA®-FL

Mantle Cell Lymphoma 17,795 MatBA®-MCL

Urogenital Cancers Cases per Year (global) CGI Test

Kidney Cancer 340,000 UroGenRA®-Kidney

Cervical Cancer Cases per Year (global) CGI Test

Cervical Cancer 528,000 FHACT®


Significant Progress in Targeted NGS Panel Pipeline

* Oncospire Genomics: a joint venture with Mayo Clinic

RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH & MARKET ENTRY

FOCUS::CLL™

FOCUS::MYELOID™ (IN COLLABORATION WITH ILLUMINA)

FOCUS::LYMPHOID™

MULTIPLE MYELOMA (VIA ONCOSPIRE*)

FOLLICULAR LYMPHOMA (VIA ONCOSPIRE*)

HEMATOLOGIC CANCERS

FOCUS::RENAL™

UROGENITAL CANCERS

FOCUS::HOTSPOT™ (INITIAL LAUNCH IN INDIA)

LUNG CANCER (VIA ONCOSPIRE*)

SOLID TUMOR

COMPREHENSIVE PHARMACOGENOMICS PANEL

PHARMACOGENOMICS (PGX)

TEST IN MARKET

TEST IN MARKET

TEST IN MARKET

11Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics

OncoSpire Genomics Developed by Cancer Genetics, Inc. and Mayo Clinic

World class NGS facility

Best in class bioinformatics

Immediately integrated into care

Disease focus and stewardship

Commercial focus and mgmt

Capital access and investment

SELECTED PROJECTS HAVE THE

POTENTIAL TO BECOME CLINICAL

STANDARD OF CARE IN NGS-BASED

ONCOLOGY MANAGEMENT

Only Joint Venture by the Mayo Clinic in

the Oncology space

Core operations leverage Mayo facilities

in Rochester, MN

$1M funded in 2013 to initiate JV, $2M

in 2014, up to $3M additional based on

milestones

Projects with 12 to 30 month

development horizon; Multiple Myeloma

panel to launch in 2015

200,000

new cases

20,920

new cases

1.6 million

new cases

Informed

Discovery

Clinical

Development

Commercial

Development

Market Entry

(with partners)

Multiple Myeloma

Follicular Lymphoma

Lung Cancer


Multiple Myeloma:Setting the New Standard with a Focused NGS Panel

A comprehensive NGS-based

panel will be developed to…

To target a major unmet need growing globally:

Identifying MGUSs that need follow-up & Tx and

determining best treatments for malignancies

Provide Greater Certainty & Reduce Complexity of

Diagnosis Replaces cyto, FISH & gene expression profiling1.

2.Earlier, More Accurate, Cost-Effective Prediction of MM

Identify mutations that predict change from MGUS to MM

• 88 genes selected for panel

• DNA sequencing complete for first

60 samples

• Analysis underway comparing 3

different analytical methods to

determine best solution

• In process of optimizing clinical

laboratory design from extraction to

reporting solution

• 3 papers in the publication process

• 2 international early-access

collaborations established


Focus::CLL™ NGS Panel

Launched in Q4 2014

Unique targeted NGS panel with 7 biomarkers for diagnosis, prognosis and patient

management

The only targeted NGS panel available for CLL/SLL

Selected for use in global clinical trial by a leading biotechnology company

18,200 new cases per year

150,000 people living with the disease

Numbers Behind the Disease

Chronic Lymphocytic Leukemia (CLL)

Small Lymphocytic Lymphoma (SLL)

Clinical Indications

(United States)

http://www.cancergenetics.com/laboratory-services/specialty-tests/focus-ngs/focuscll/


Focus::Myeloid™ NGS Panel

Launched in Q1 2015

Comprehensive NGS panel with 54 biomarkers that provides actionable information

for improved diagnosis, prognosis, and risk stratification

Delivers faster results on biomarkers in current diagnostic and treatment guidelines

Expands therapy options for patients with appropriate enrollment in clinical trials

Selected for use in multiple clinical trials

54,000 new cases per year

274,000 people living with the disease

Numbers Behind the Disease

Acute myeloid leukemia (AML)

Myelodysplastic syndrome (MDS)

Myeloproliferative neoplasms (MPN)

Clinical Indications

(United States)

http://www.cancergenetics.com/laboratory-services/specialty-tests/focus-ngs/focusmyeloid/


MatBA®-CLL/SLL Drives Improved Management of Patients

with Chronic Lymphocytic Leukemia (CLL)

Favorable/

Intermediate(no distinction)

Unfavorable85%

15%

FISH

4 Genomic Aberrations

Risk stratification by FISH, classifies

patients into only two groups:

Favorable/Intermediate

(no distinction)

Unfavorable

38% of cases are

favorable falling

under "watch &

wait" approach.

8% of unfavorable

cases missed by

FISH are caught by

MatBA®-CLL/SLL.23%

39%

38%

20 Genomic Aberrations

Favorable

Intermediate

Unfavorable

MatBA®-CLL/SLL is both CLIA & NYS licensed

to stratify patients into three distinct risk groups:

Favorable

Intermediate

Unfavorable


[Kanti Rai, Nicholas Chiorazzi,

Jacqueline Barrientos]

Significance of Current Prognostic Markers in CLL in

the B-Cell Receptor Signaling Pathway Inhibitor Era

Zydelig™[Idelalisib (PI3K-delta)]

FDA Approved For CLL in the relapse setting

when considering Rituximab alone

Collaborative project in progress at CGI

Insights will be integrated into our

CLL Complete™

IMBRUVICA™[Ibrutinib (BTK)]

FDA Approved for CLL with 17p loss and in the

relapse setting where two prior therapies have failed

Genomic alterations associated with resistance

Acquired Mutations during therapy in BTK

Gene (C481S), PLCG2 (R665W)

Deletion of 8p

Gain of 3q

B-CELL RECEPTOR SIGNALING

PATHWAY INHIBITORS


Solution

UroGenRA®-Kidney Can Guide Management of Patients

with Renal Masses and Appropriate Treatment Selection

Development of diagnostic algorithm

>600 RCC malignant subtypes (in-silico: SNP)

>100 malignant and benign renal neoplasms (in-house: aCGH & FISH)

Retrospective in-house FFPE validation (n>190) CCF

diagnostic yield

diagnostic sensitivity to distinguish benign from malignant renal neoplasms

sensitivity to distinguish malignant RCC subtypes

Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC

Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to

surgical intervention

Men and women with renal masses often

undergo unnecessary nephrectomy for accurate

diagnosis and experience delay in treatment

Problem

UroGenRA® will detect genomic aberrations in a single assay

permitting accurate diagnosis (benign vs malignant, and malignant

subtype) guiding appropriate management and treatment strategies

[C. Magi-Galluzzi and E. Klein]

[J. Coleman and J. Durack]


FHACT® Fits Directly into Today’s Cervical Cancer

Screening Workflow

Today, all these women are referred for colposcopy.

Not referred

for colposcopy

Referred for

colposcopy

PROGRESS to a higher grade andincreased risk for cancer within 10-30years of the infection.

REGRESS within 2 years ofthe infection.

FHACT®

Results:Normal

FHACT®

Results:Abnormal

Today, all HPV+ women with abnormal

Pap results are referred for colposcopy

Several cervical cancer tests are

available but the need for less invasive

and better informed treatment exists

FHACT® helps triage before colposcopy

No resampling

Fewer women referred for colposcopy

Reduced healthcare costs


FISH-based HPV-Associated Cancer Test

FHACT® assesses non-random genomic alterations associated with

progression of lesion.

Gain of 3q26 (TERC) has been detected with increasing frequency in

cervical lesions with increasing severity and is observed in about 75% of

cervical cancers.[1-2]

Gains of 5p15, 20q13 & chr 7 share a similar pattern of appearance in

precancerous cytology specimens by FISH (40-45%, 20q13, and 15%

respectively).[3-4]

Performed on remnant liquid based cytology.

Gain at any of the FHACT® loci is detected in up to 89.5% of all

cervical cancers.[5]

FHACT® presents the highest sensitivity on the market (4 loci).

1. Heselmeyer-Haddad K, et al. (2005). Am. J. Pathol. , 166, 1229-1238

2. Seppo A., et al. (2009) Gynecol Oncol, 114, 80-83

3. Scotto, L., et al. (2008). Mol Cancer, 7, 58.

4. Luhn P, et al. (2013). Gynecol Oncol, 130, 595-600.

5. The Cancer Genome Atlas (TCGA) (http:/cancergenome.nih.gov)

FHACT® Can Aid in Identifying Women with Markers of

High Grade Lesions (Cervical Cancer)

FHACT® Loci:

3q26 gain (red)

5p15 gain (green)

Cen7 (aqua)

20q13 gain (gold)


Community Hospitals

Regional Cancer Centers

Oncologists and Pathologists

• Continue to growing sales force that calls on hospitals

and regional laboratories

• Plan development of national footprint through

Expand Dx™

Biotechnology Companies

Pharmaceutical Companies

• Leverage clinical infrastructure and proprietary product

portfolio for testing services that support clinical trials

• Expand sales emphasis of Select One®

Emerging Markets• Enhance distributor base in select emerging economies

• Partner with leading local cancer care providers and

hospitals to provide probes, arrays and clinical services

• Collaborate to create and validate microarrays and

other proprietary products

• Accelerate launch of large scale studies

Universities and Research Centers

Large, Targeted Market Opportunities

Commercialization StrategyTarget Markets


• Delivers better outcomes to community

hospitals and laboratories

• Enables community hospitals to bring

“state-of-the-art” genomic testing to

patients

• Brings personalized medicine to the

community hospital vs. just at

academic and teaching hospitals

• Allows community hospitals to keep

patients and treat them locally

• Improving care and quality is critical to

maintaining reimbursement for

community hospitals

$600,000 - $800,000 USD in Testing

Opportunity on Average per Hospital

Expanding & Developing Cancer Care is a

Top Priority for Hospital CEOs & CFOs

4,000 to 5,000 Community Hospitals

& Laboratories in the U.S.

85% Of All U.S. Cancer Patients are Initially

Diagnosed in Community Hospitals &

Laboratories

Unique Service Offering Developed to Enable Community

Hospitals to Improve Cancer Outcomes & Treat Patients Locally


Strong Growth in Clinical Trial Contracts with Oncology

Programs at Leading Biotech & Pharma Companies

Approximate expected future revenues under signed contracts with biotechnology and pharma

customers for testing and services to support currently planned clinical trials.

CGI IS ACTIVELY PROVIDING TESTING, GENOMIC SERVICES, AND BIOMARKER

SUPPORT FOR

December 2013December 2012 December 2014 March 2015


Strong History of Growth Revenue Trends (2014 Year End and Q1 2015)

Year End Total Revenue ($Mn) Q1 Total Revenue ($Mn)

$10.2 Mn revenue, up 54% Yr./Yr.

Biopharma revenue grew 112% Yr./Yr.

$3.0

$4.3

$6.6

10.2

2011 2012 2013 2014

$

36%

CAGR

201420132011 2012

$4.4 Mn revenue, up 206% Qtr./Qtr.

Biopharma revenue grew 578% Qtr./Qtr.

$0.8

$1.2$1.4

$4.4

Q1, 2012 Q1, 2013 Q1, 2014 Q1, 2015Q1, 2015Q1, 2014Q1, 2013Q1, 2012

53%

CAGR


Summary Statement of Operations

Income Statement Item ($ in Thousands)

Q1 2013 Q1 2014 Q1 2015

Revenue $1,219 $1,430 $4,370

Gross Profit 149 140 1,229

Gross Margin (%) 12% 10% 28%

Research & Development (R&D) 491 597 1,278

Sales & Marketing (S&M) 397 749 1,116

General & Administrative (G&A) 1,571 2,731 2,987

Operating Profit (Loss) (2,309) (3,936) (4,152)

Net Income (Loss) 2,360 (2,486) (4,278)

Balance Sheet Information Actual 03/31/15

All Cash* $28,612

Stockholders’ Equity 30,972

$ in thousands * All cash includes $6,300 of restricted cash.

$6,000 of that is now unrestricted as of May 7, 2015.

(Cancer Genetics, Inc. 2014 YE 10Q, page 77)


Revenues by Category

76%

20%

4%Q1

2015

BIOPHARMA SERVICES

CLINICAL SERVICES

DISCOVERY SERVICES

$10.2 Mn $4.4 Mn

Launched new NGS panels, including

Focus::Myeloid™

Repositioning of Go-To Market Strategy to

concentration on clinical sales

New research studies with leading cancer

centers and academic institutions

Focus::Hotspot™ NGS panel for solid tumors

adopted in multiple research programs in India

Selected to power molecular and biomarker

testing for six clinical trials

Focus::CLL™ chosen for global clinical trial

by leading biotechnology company

$3.3 M

$873 K

$166 K


Consistent Achievement of Milestones Expected

in Coming Quarters

Increasing covered lives market access through additional payers & health care organizations

Additional international agreements for FHACT® distribution and co-marketing partnerships in key geographies

Launching multi-marker NGS panel for lymphoid malignancies

Multiple Myeloma NGS panel launch, Oncospire Second half of 2015

Lymphoid, Myeloid and CLL Panels - Additional data and results to support clinical usage, patient value and payor

coverage

FHACT® - Additional data from a study conducted in conjunction with NCI and more published papers focused on

FHACT®, including a health economic study

Additional news on biopharma partners & relationships

Major collaborations with US & Asia biopharma companies


Scientific Advisory Board

Andrea Califano, Ph.D.Chairman of the Columbia Initiative for Systems Biology

Associate Director for Bioinformatics, Herbert Irving Comp. Cancer Ctr

Timothy A. Chan, M.D., Ph.D.Principal Investigator, Human Oncology and Pathogenesis Program at

Memorial Sloan-Kettering Cancer Center

Riccardo Dalla-Favera, M.D.Director, Institute for Cancer Genetics at Columbia University

Vundavalli V. Murty, Ph.D.Director, Cancer Cytogenetic Laboratory and Molecular Pathology at

Columbia University

Hans-Guido Wendel, M.D.Principal Investigator, Cancer Genetics Laboratory at Memorial Sloan-

Kettering Cancer Center

Howard McLeod, PharmDMedical Director, DeBartolo Family Personalized Medicine Institute, Moffitt

Cancer Center

Panna Sharma President & CEO

• 15+ years as advisor to global life science & healthcare cos.

• General Manager of Oncospire Genomics, JV with Mayo Clinic

• Founded TSG Partners

• Chief Strategy Officer, iXL (IIXL)

Edward J. Sitar Chief Financial Officer & Treasurer

• 30+ yrs in finance & deal making in the healthcare industry

• Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation

(Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers & Lybrand

Jane Houldsworth, Ph.D. Vice President of R&D

• 25+ years in translational oncology research

• Published 50+ articles, 4 patents

• NIH grantee

Rob Fannon Vice President of Operations

• 10+ years operations, client management, molecular test & panel

development, and biorepository management

• Roche Molecular Systems, BioServe Biotechnologies, Ltd., Stansberry &

Associates Investment Research

John Pappajohn [Chairman] | Edmund Cannon | Raju Chaganti, Ph.D. | Geoffrey Harris

Howard McCleod, Pharm.D. | Franklyn Prendergast, M.D., Ph.D. | Panna Sharma | Michael J. Welsh M.D.

Board of Directors

Officers & Management Team

Experienced and Focused Management and Boards


• Strong and growing portfolio in molecular-focused patents for disease identification & stratification

• IP-based on unique algorithms across a broad group of chromosomal regions

• Validation of specific clinical endpoints that are associated with particular disease

outcomes or decisions

• Filing and maintenance of trademark portfolio

Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms• US Issued Patent 8,580,713• US Issued Patent 8,557,747• Europe 10803548.6• India 6657/DELNP/2012• Canada 2,785,656

Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH)

• US Issued Patent 7,585,964• US Issued Patent 7,964,345• Canada 2,447,320 – Foreign Counterpart Patent

Panel for the Detection & Differentiation of Renal Cortical Neoplasms• US Issued Patent 8,603,948• US Issued Patent 8,716,913• Europe 08844570.5

Methods for Detecting Human Papilloma Virus-Associated Cancers• US Issued Patent 8,865,882 • US Issued Patent 8,883,414• PCT/US2011/050681

Methods and Tools for the Diagnosis of Female Gynecological Cancers and Precancers

• US 61/581,350

IP Position and Detailed Global Strategy

Thank youNasdaq

(CGIX)

CGI Headquarters

Meadows Office Complex

201 Route 17 North, 2nd Fl.

Rutherford, NJ 07070

Phone: +1 201-528-9200

Fax: +1 201-528-9235

RUTHERFORD, NJ

Research Triangle Park

133 Southcenter Court, S.400

Morrisville, NC 27569

Phone: +1 919-465-0100

Fax: +1 919-465-0554

RALEIGH, NC

#3-1-135 / 1A CNR Complex

Mallapur Main Road, R.R. Dst.

Hyderabad – 500 076, Telangana

Toll-free: +91 040-2717-8178

Fax: +91 040-2717-8176

HYDERABAD, INDIA

781 Cai Lun Road, Room 803

Shanghai 201203

P.R. China

Toll-free: +91 040-2717-8178

Fax: +91 040-2717-8176

SHANGHAI, CHINA

For further information, please contact us at [email protected]

mailto:[email protected]